Linked Life Data

3058601

Source:http://linkedlifedata.com/resource/pubmed/id/3058601

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
89
pubmed:dateCreated
1989-1-18
pubmed:abstractText
8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL). We have developed monoclonal antibodies which specifically recognize 8-MOP-modified DNA and do not cross-react with unmodified DNA or free 8-MOP. Highly sensitive, competitive enzyme-linked immunosorbent assays (ELISA) have been developed with both colour and fluorescence endpoint detection for quantification of DNA adducts in biological samples. In addition, immunofluorescence and flow cytometric techniques have been developed to visualize adducts in tissues and cells. These techniques have been validated in keratinocytes treated in culture and in animals treated in vivo with 8-MOP and ultraviolet A (UVA) light. Adduct levels have also been monitored in skin biopsies and lymphocytes of patients with psoriasis and lymphoma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-5038
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
333-40
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Detection and quantification of 8-methoxypsoralen-DNA adducts.
pubmed:affiliation
Comprehensive Cancer Center, School of Public Health, Columbia University, New York, NY.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.